

TITLE: OLIGOPEPTIDE TREATMENT OF
ANTHRAX

Inventor: Khan et al.
Serial No.: 10/029,206
Docket No.: 2183-5222US

1/39





Fig. 1





Fig. 2



**MHC-II EXPRESSION OF CD11c POSITIVE BM CELLS
(EX VIVO)**




Fig. 3

BONE MARROW CELL YIELD (IN VITRO)





Fig. 4

+

TITLE: OLIGOPEPTIDE TREATMENT OF ANTHRAX

Inventor: Khan et al.
Serial No.: 10/029,206
Docket No.: 2183-5222US

3/39



BONE MARROW CELL YIELD (IN VITRO)




Fig. 5

BONE MARROW CELL YIELD (IN VITRO)





Fig. 6

TITLE: OLIGOPEPTIDE TREATMENT OF
ANTHRAXInventor: Khan et al.
Serial No.: 10/029,206
Docket No.: 2183-5222US

4/39



BONE MARROW CELL YIELD (IN VITRO)




Fig. 7



MHC-II EXPRESSION OF CD11c POSITIVE BM CELLS
(IN VITRO)

Fig. 8

TITLE: OLIGOPEPTIDE TREATMENT OF
ANTHRAX

Inventor: Khan et al.
Serial No.: 10/029,206
Docket No.: 2183-5222US

5/39



MHC-II EXPRESSION OF CD11c POSITIVE BM CELLS
(IN VITRO)




Fig. 9

MHC-II EXPRESSION OF CD11c POSITIVE BM CELLS
(IN VITRO)







Fig. 10


TITLE: OLIGOPEPTIDE TREATMENT OF
ANTHRAXInventor: Khan et al.
Serial No.: 10/029,206
Docket No.: 2183-5222US

6/39

**MHC-II EXPRESSION OF CD11c POSITIVE BM CELLS
(IN VITRO)****Fig. 11****'UNATTACHED' BONE MARROW CELL YIELD
(EX VIVO)****Fig. 12**

TITLE: OLIGOPEPTIDE TREATMENT OF
ANTHRAX
Inventor: Khan et al.
Serial No.: 10/029,206
Docket No.: 2183-5222US

7/39



**'UNATTACHED' BONE MARROW CELL YIELD
(EX VIVO)**




Fig. 13

**'ATTACHED' BONE MARROW CELL YIELD
(EX VIVO)**





Fig. 14

TITLE: OLIGOPEPTIDE TREATMENT OF ANTHRAX

Inventor: Khan et al.
Serial No.: 10/029,206
Docket No.: 2183-5222US

8/39



'ATTACHED' BONE MARROW CELL YIELD (EX VIVO)




Fig. 15

'UNATTACHED' BONE MARROW CELL YIELD (IN VITRO-NOD)





Fig. 16


**TITLE: OLIGOPEPTIDE TREATMENT OF
ANTHRAX**

Inventor: Khan et al.
Serial No.: 10/029,206
Docket No.: 2183-5222US

9/39



**'ATTACHED' BONE MARROW CELL YIELD
(IN VITRO-NOD)**



TREATMENT

Fig. 17

TITLE: OLIGOPEPTIDE TREATMENT OF ANTHRAX

Inventor: Khan et al.

Serial No.: 10/029,206

Docket No.: 2183-5222US

10/39





Fig. 19




Fig. 18

TITLE: OLIGOPEPTIDE TREATMENT OF
ANTHRAX

Inventor: Khan et al.
Serial No.: 10/029,206
Docket No.: 2183-5222US

11/39





Fig. 21




Fig. 20

TITLE: OLIGOPEPTIDE TREATMENT OF
 ANTHRAX
 Inventor: Khan et al.
 Serial No.: 10/029,206
 Docket No.: 2183-5222US

12/39





Fig. 23




Fig. 22





Fig. 25








Fig. 24



TREATMENT

Fig. 26



TREATMENT



Fig. 27

TITLE: OLIGOPEPTIDE TREATMENT OF
ANTHRAX

Inventor: Khan et al.
Serial No.: 10/029,206
Docket No.: 2183-5222US

16/39

+



TREATMENT

Fig. 28

+

TITLE: OLIGOPEPTIDE TREATMENT OF
ANTHRAX

Inventor: Khan et al.
Serial No.: 10/029,206
Docket No.: 2183-5222US

17/39







Fig. 29

TITLE: OLIGOPEPTIDE TREATMENT OF
ANTHRAX

Inventor: Khan et al.
Serial No.: 10/029,206
Docket No.: 2183-5222US

18/39



TREATMENT

Fig. 30

4,183,522 US 2003-10-23

TITLE: OLIGOPEPTIDE TREATMENT OF
ANTHRAX
Inventor: Khan et al.
Serial No.: 10/029,206
Docket No.: 2183-5222US

19/39





Fig. 31

+

20/39






Fig. 32

TITLE: OLIGOPEPTIDE TREATMENT OF
ANTHRAX

Inventor: Khan et al.
Serial No.: 10/029,206
Docket No.: 2183-5222US

21/39



Stand#5-69 RT:
0.75-0.96 AV.9 NL:
1.28E7F+pFull ms1
[200.00-2000.00]

Stand#4-68 RT:
0.26-0.74 AV.41 NL:
5.74E6F+pFull ms2
416.30@80.00
[110.00-420.00]

Stand#1 RT:0.01 AV.
1 NL: 1.57E6F+pFull
ms3 416.30@80.00
242.00@80.00
[65.00-420.00]

MSn Analysis of NMPF-4 peptide





Fig. 33

TITLE: OLIGOPEPTIDE TREATMENT OF ANTHRAX

Inventor: Khan et al.
Serial No.: 10/029,206
Docket No.: 2183-5222US

22/39



Fraction from nuclear extract of LPS stimulated RAW264.7 cells





Fig. 34

TITLE: OLIGOPEPTIDE TREATMENT OF ANTHRAX


Inventor: Khan et al.
Serial No.: 10/029,206
Docket No.: 2183-5222US

23/39



Fraction from nuclear extract of NMP-4+LPS stimulated RAW264.7 cells

lps-NAK4-push #82-145 RT: 0.57-1.00 AV:64 NL:3.68E5
T:~p Full ms [300.00-500.00]



lps-NAK4-push #159-173 RT: 1.25-1.69 AV:13 NL:2.99E3
F:~p Full ms2416.10@80.00 [110.00-500.00]





Fig. 35

TITLE: OLIGOPEPTIDE TREATMENT OF ANTHRAX

Inventor: Khan et al.
Serial No.: 10/029,206
Docket No.: 2183-5222US

24/39



Heart-rate (beats per minute) of Ri429 during sepsis





Fig. 36

TITLE: OLIGOPEPTIDE TREATMENT OF
 ANTHRAX
 Inventor: Khan et al.
 Serial No.: 10/029,206
 Docket No.: 2183-5222US

25/39



Blood pressure (mmHg) of R1429 during sepsis without treatment





Fig. 37

TITLE: OLIGOPEPTIDE TREATMENT OF
ANTHRAX
Inventor: Khan et al.
Serial No.: 10/029,206
Docket No.: 2183-5222US

26/39



Systolic-Diastolic bp of Ri429 during sepsis without treatment





Fig. 38

TITLE: OLIGOPEPTIDE TREATMENT OF
ANTHRAX

Inventor: Khan et al.
Serial No.: 10/029,206
Docket No.: 2183-5222US

27/39



SpO₂ of Ri429 during sepsis without treatment





Fig. 39

28/39

+



Heart-rate (beats per minute) of Ri459 during sepsis





Fig. 40

+

TITLE: OLIGOPEPTIDE TREATMENT OF
 ANTHRAX
 Inventor: Khan et al.
 Serial No.: 10/029,206
 Docket No.: 2183-5222US

29/39



Blood pressure (mmHg) of Ri459 during sepsis and treatment with NMPF





Fig. 41

TITLE: OLIGOPEPTIDE TREATMENT OF
ANTHRAX

Inventor: Khan et al.
Serial No.: 10/029,206
Docket No.: 2183-5222US

30/39



Systolic- Diastolic bp of Ri459 during treatment with NMPF





Fig. 42

TITLE: OLIGOPEPTIDE TREATMENT OF
ANTHRAX

Inventor: Khan et al.
Serial No.: 10/029,206
Docket No.: 2183-5222US

31/39



SpO₂ of Ri459 during sepsis and treatment with NMPF





Fig. 43

32/39



Heart-rate (beats per minute) of Ri427 during sepsis





Fig. 44

TITLE: OLIGOPEPTIDE TREATMENT OF
ANTHRAX
Inventor: Khan et al.
Serial No.: 10/029,206
Docket No.: 2183-5222US



33/39

Blood pressure (mmHg) of Ri427 during sepsis and treatment with NMPF





Fig. 45



34/39

Systolic-Diastolic bp of Ri427 during treatment with NMPF





Fig. 46



SpO₂ of R1459 during sepsis and treatment with NMPF





Fig. 47



36/39




Fig. 48A




Fig. 48B




Fig. 48C

37/39




Fig. 49A




Fig. 49B




Fig. 49C



TITLE: OLIGOPEPTIDE TREATMENT OF
ANTHRAX


Inventor: Khan et al.

Serial No.: 10/029,206

Docket No.: 2183-5222US

38/39

**Fig. 50**

TITLE: OLIGOPEPTIDE TREATMENT OF
ANTHRAX

Inventor: Khan et al.

Serial No.: 10/029,206

Docket No.: 2183-5222US

39/39

GTT




Fig. 51A

Blood Glucose (Fasting)




Fig. 51B